Skip to main content

Susanne Liewer, PharmD, BCOP

Clinical Pharmacy Coordinator
Stem Cell Transplant, Nebraska Medicine
Department of Pharmacy, Omaha
Clinical Associate Professor
University of Nebraska Medical Center
College of Pharmacy, Omaha, NE

Authored Items

A Commentary on the Efficacy of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
By Susanne Liewer, PharmD, BCOP
Faculty Perspectives March 2013 Vol 4 No 2
Bendamustine is an active chemotherapy agent that has been studied for many years in a variety of malignancies; however, it has only been approved for use in the United States since 2008.1 Structurally, bendamustine shares similarities with both purine analogs and alkylating agents. Read More ›
The Developing Treatment Role of Bendamustine
By Susanne Liewer, PharmD, BCOP
Faculty Perspectives June 2013 Vol 4 No 4
Hematologic Cancers
Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors. Read More ›
Toxicity of Bendamustine Therapy
By Susanne Liewer, PharmD, BCOP
Faculty Perspectives May 2013 Vol 4 No 3
Drug Updates
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). Read More ›